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Abstract
Background: Excessive autoantibody production characterizing systemic lupus erythematosus (SLE) occurs
irrespective of the disease’s clinical status and is linked to increased lymphocyte apoptosis. Herein, we tested
the hypothesis that defective DNA damage repair contributes to increased apoptosis in SLE.
Methods: We evaluated nucleotide excision repair at the N-ras locus, DNA double-strand breaks repair and
apoptosis rates in peripheral blood mononuclear cells from anti-dsDNA autoantibody-positive patients (six with
quiescent disease and six with proliferative nephritis) and matched healthy controls following ex vivo treatment
with melphalan. Chromatin organization and expression levels of DNA repair- and apoptosis-associated genes
were also studied in quiescent SLE.
Results: Defective nucleotide excision repair and DNA double-strand breaks repair were found in SLE, with lupus
nephritis patients showing higher DNA damage levels than those with quiescent disease. Melphalan-induced
apoptosis rates were higher in SLE than control cells and correlated inversely with DNA repair efficiency. Chromatin
at the N-ras locus was more condensed in SLE than controls, while treatment with the histone deacetylase inhibitor
vorinostat resulted in hyperacetylation of histone H4, chromatin decondensation, amelioration of DNA repair
efficiency and decreased apoptosis. Accordingly, genes involved in DNA damage repair and signaling pathways, such
as DDB1, ERCC2, XPA, XPC, MRE11A, RAD50, PARP1, MLH1, MLH3, and ATM were significantly underexpressed in SLE
versus controls, whereas PPP1R15A, BARD1 and BBC3 genes implicated in apoptosis were significantly overexpressed.
Conclusions: Epigenetically regulated functional abnormalities of DNA repair machinery occur in SLE, regardless of
clinical disease activity, and may promote lymphocyte apoptosis. Approaches to correct these abnormalities may be
of therapeutic value in SLE.
Keywords: Systemic lupus erythematosus, Nucleotide excision repair, DNA double-strand breaks repair, Chromatin
organization, Apoptosis, Histone deacetylase inhibitor
Background
The prototypic systemic autoimmune disease, systemic
lupus erythematosus (SLE), is characterized by loss of
immunological tolerance to self-nuclear antigens and ab-
normal T- and B-cell responses, which are attributed to
genetic and epigenetic causes [1]. Excessive autoantigen
presentation and autoantibody production is considered
a central pathogenetic mechanism of SLE [2]. Significant
diversity in organ involvement, disease activity, severity
and responsiveness to treatment are common [3]. Of
note, the production of myriads of autoantibodies in
human SLE may precede the onset of clinical disease by
many years and is facilitated by accumulation of dead
cells due to dysregulated apoptosis [1, 4].
Every day, each of our cells is faced with at least 104
DNA lesions and their efficient repair is a mandatory
biological process to preserve cell survival and function
[5]. The genomic integrity is maintained by a network of
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DNA damage response and repair pathways, a compre-
hensive signaling process that determines the cell's abil-
ity to repair DNA damage or to undergo mutation(s) or
apoptosis [6]. The wide diversity of DNA lesion types
necessitates multiple, largely distinct DNA repair mecha-
nisms. For example, nucleotide excision repair executes
the repair of DNA lesions induced by UV light, polycyc-
lic aromatic hydrocarbons, heavy metals such as plat-
inum and cadmium, and by other sources that form
bulky DNA lesions that distort the DNA helix [7]. On
the other hand, for DNA double-strand breaks, which
are introduced by exogenous agents such as ionizing ra-
diation and therapeutic drugs as well as by cellular pro-
cesses such as V(D)J recombination, class switch
recombination, stalled replication forks and reactions
that generate reactive oxygen species [8], two principal
repair mechanisms are used. The first is the homologous
recombination, an error-free repair pathway that uses
DNA homology to direct DNA repair, and the second is
the nonhomologous end joining, a straightforward reli-
gation of broken DNA ends without any requirement
for a template [5]. Defective nucleotide excision repair
has been indeed reported in SLE [9–11], whereas the
majority of B lymphoblastoid cell lines derived from
children with SLE gave evidence of inefficient or delayed
kinetics of DNA double-strand breaks repair [12]. Our
recent study has shown that circulating mononuclear
cells from patients with a severe SLE complication, such
as lupus nephritis, are characterized by higher intrinsic
DNA double-strand breaks accumulation compared to
healthy controls, possibly due to increased susceptibility
of these cells to develop these DNA lesions and/or an
impaired repair [13].
Herein, we considered that increased apoptosis in SLE
could be due, at least in part, to defective mechanisms
of DNA damage repair, thus providing an additional pu-
tative pathogenetic mechanism in systemic autoimmun-
ity. Indeed, we found that nucleotide excision repair and
DNA double-strand breaks repair mechanisms are de-
fective in patients with either clinically quiescent disease
or proliferative lupus nephritis, and strongly correlate
with increased apoptosis. Notably, treatment of lupus
mononuclear cells with the histone deacetylase inhibitor
vorinostat resulted in amelioration of DNA repair effi-
ciency and decreased apoptosis. In line with these find-
ings, genes involved in DNA repair and signaling
pathways were found downregulated, whereas genes




Peripheral blood mononuclear cells (PBMCs) from 12
patients (10 women) who fulfilled American College of
Rheumatology criteria for SLE and had high serum titers
of anti-double-stranded DNA autoantibodies at the time
of sampling were studied. Six patients (all women, aged
between 24 and 45 years, with disease duration ranging
between 2 and 11 years) were selected on the basis of
the presence of clinically quiescent disease for at least 6
months prior to sampling (SLE disease activity index
Selena modification score of 6 or less, in the absence of
any lupus-related clinical manifestation) under daily
therapy with hydroxychloroquine only (n = 3), or in
combination with 5 mg or less of prednisolone (n = 3).
Six other patients (four women, aged between 21 and 59
years, with disease duration ranging between 1 and 15
years) were selected on the basis of the presence of pro-
liferative glomerulonephritis; their characteristics, dis-
ease status, and medications have been described in
detail elsewhere [13]. Twelve apparently healthy individ-
uals, who were antinuclear antibody negative and
matched 1:1 for age and gender to the patients, were
studied in parallel.
Cell cultures
Freshly isolated PBMCs were stimulated into prolifera-
tion using phytohemagglutinin (PHA; 10 μg/ml) for 48
hours and then treated with 100 μg/ml melphalan for 5
min at 37 °C in complete RPMI-1640 medium supple-
mented with 10 % fetal bovine serum (FBS), 100 units/
ml penicillin, 100 μg/ml streptomycin and 2 mmol/l L-
glutamine. Cells were subsequently incubated in drug-
free medium for various times (0–48 h), harvested, and
stored at −70 °C. In some experiments, PBMCs were ex-
posed to 2.5 μg/ml of vorinostat (suberoylanilide hydro-
xamic acid; Millipore Sigma, St. Louis, MO, USA) for 24
h [14], or 10 μg/ml a-amanitin (Millipore Sigma) for 6 h
[15], treated with melphalan as above, harvested and
stored at −70 °C.
Nucleotide excision repair measurement
The N-ras gene-specific nucleotide excision repair
was evaluated by the monofunctional binding of the
drug melphalan to a single site in the DNA molecule
(monoadducts) at various time points, as described
elsewhere [16].
DNA double-strand breaks repair measurement
For the evaluation of DNA double-strand breaks the im-
munofluorescence antigen staining and confocal laser
scanning microscope analysis was used as described pre-
viously [13]. Briefly, aliquots of 2 × 104 PBMCs were
stimulated into proliferation using PHA, treated as
described above, adhered to coverslip, fixed and stored
at −70 °C until the analysis of γH2AX and Rad51. Cells
were incubated with antibodies against γH2AX (serine-
139, Cell Signaling, Danvers, MA, USA) or Rad51 (Santa
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Cruz Biotechnology, Dallas, TX, USA), washed, incu-
bated with fluorescent secondary antibodies (Alexa Fluor
488 goat anti-mouse IgG; Abcam, Cambridge, UK) and
images were visualized with a Leica TCS SP-1 confocal
laser scanning microscope (Leica, Wetzlar, Germany).
Foci were manually counted in 200 cells/treatment con-
dition and results were expressed as the mean γH2AX
or Rar51 foci per cell [mean ± standard deviation (SD)]
from three independent experiments.
Micrococcal nuclease digestion-based analysis of
chromatin condensation
Nuclei were isolated from freshly isolated, untreated
PBMCs (5 × 104) and digested with 1 unit of micrococcal
nuclease (Millipore Sigma) for 0, 1, 2, 5 and 10 min at
37 °C. DNA was purified, separated in 1.5 % agarose gel,
transferred onto nitrocellulose, and hybridized with the
appropriate labeled probe [17].
Western blot analysis
Cells were harvested after treatment with various doses
of vorinostat for 24 hours at 37 °C, rinsed in ice-cold
phosphate-buffered saline (PBS), and lysed in buffer con-
taining 50 mM HEPES (pH 7.9), 0.4 M NaCl, 1 mM
EDTA, 2 μg/ml leupeptin, 2 μg/ml aprotinin, 5 μg/ml
benzamidine, 0.5 mM phenylmethylsulfonyl fluoride
(PMSF), and 1 % NP-40, followed by SDS-PAGE on
12 % polyacrylamide gels. Subsequently, the proteins
were transferred to nitrocellulose membranes, which
were incubated for 40 min at room temperature with
nonfat dry milk (5 %) in 1 × Tris-buffered saline
(TBS) followed by incubation with specific primary
antibodies to nonacetylated histone H4, acetylated his-
tone H4, and beta actin (Cell Signaling) overnight at 4 °C.
Then, the membranes were washed with 0.3 % bovine
serum albumin in 1 × TBS and incubated with horseradish
peroxidase-conjugated secondary antibodies for 2 h at
room temperature. After washing with 1 × TBS, the
bound antibody complexes were visualized using the
Western Blotting Detection Kit ECL Plus (Amersham,
Little Chalfont, UK) and XOMAT-AR film (Kodak,
Rochester, NY, USA).
Apoptosis assay
Cells were treated with various doses of melphalan
(0–200 μg/ml) for 5 min, followed by 24 h post-
incubation time. Then, the Cell Death Detection
ELISA-PLUS kit (Roche Diagnostics Corp., Basel,
Switzerland) was used to determine apoptosis accord-
ing to the protocol provided by the manufacturer.
RT2 Profiler™ PCR Array
Total RNA was extracted from freshly isolated untreated
PBMCs using the Qiagen RNeasy Mini Kit (Qiagen,
Venlo, the Netherlands) according to the manufacturer’s
instructions and stored at −80 °C until use. For PCR
array analysis, the RT2 Profiler™ PCR Array (Qiagen) of
84 genes related to the DNA damage signaling pathway
was utilized. Total RNA (200 ng) was reverse transcribed
using the RT2 First Strand kit following the manufac-
turer’s instructions. Resulting cDNA was diluted in
nuclease-free water and added to RT2 SYBR Green
Fluor qPCR Mastermix (Qiagen), which was subse-
quently aliquoted to each well of the PCR array for
quantitative PCR. Thermal cycling and fluorescence
detection were performed using a Biorad iQ™5 (Bio-
Rad Laboratories, Hemel Hempstead, UK). Cycling
conditions were: 10 min denaturation at 95 °C
followed by 40 cycles of 15 sec at 95 °C and 1 min at
60 °C. Six healthy control samples and six quiescent
SLE patients samples were run on individual plates
and data were analyzed using the RT2 Profiler PCR
Array Data Analysis Webportal (http://pcrdataanaly
sis.sabiosciences.com/pcr/arrayanalysis.php). Two inde-
pendent experiments were performed for each sample.
Systems biology statistical analysis
The transcripts presenting statistically significant differ-
ential expression (p < 0.05) were analyzed through the
use of Qiagen’s Ingenuity® Pathway Analysis (IPA®,
Qiagen, Redwood City, CA, USA, www.qiagen.com/in
genuity) considering all direct and indirect relationships
in the Ingenuity Knowledge base obtained only from
experimentally verified information. Canonical path-
ways underwent enrichment analysis and the corre-
sponding p values were calculated (p values < 0.05
were considered significant).
Statistical analysis
The efficiency of DNA repair and the induction of apop-
tosis were compared between groups of individuals using
the Wilcoxon rank sum test. Correlations between
melphalan-induced DNA damage and induction of apop-
tosis were assessed by the linear regression analysis. A p
value less than 0.05 was considered statistically significant.
P values indicating statistical significance of the gene ex-
pression levels where corrected for multiple comparisons
(FDR correction; Additional file 1: Table S1) [18].
Results
Nucleotide excision repair and DNA double-strand breaks
repair are defective in SLE, regardless of disease activity
level
In the present study, two major DNA repair mechanisms
were evaluated in SLE patients, i.e., nucleotide excision
repair and DNA double-strand breaks repair. Based on
our previous experience, we used the genotoxic drug
melphalan as a tool to induce (a) DNA lesions such as
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the monofunctional binding of this drug to a single site
in the DNA molecule (monoadducts), which are almost
exclusively repaired by nucleotide excision repair [16],
and (b) DNA double-strand breaks, which are indirectly
formed as a consequence of melphalan-induced oxida-
tive stress [19] and as intermediates in the repair of
melphalan-induced DNA damage [20, 21].
First, the efficiency of the nucleotide excision repair
was measured in six patients with quiescent disease and
their matched controls. Since we have previously shown
that the efficiency of nucleotide excision repair at the N-
ras locus strongly correlates with melphalan-induced
apoptosis in PBMCs from healthy controls [22], the re-
pair kinetics of N-ras-specific monoadducts were
followed for up to 48 h using Southern blot analysis
(Fig. 1a). In all subjects, similar formation of monoad-
ducts was found at the end of the 5-min melphalan
treatment. Thereafter, their levels were decreased, with
the removal capacity being higher in healthy controls
than in quiescent SLE patients and lowest in patients
with active proliferative nephritis (Fig. 1b). In accord-
ance to these data, monoadducts burden (expressed as
the area under the curve for DNA adducts during the
whole experiment), a parameter strongly correlating with
the cytotoxicity of genotoxic agents [23], was signifi-
cantly higher in quiescent SLE patients compared to
healthy controls; maximal values were observed in
patients with active proliferative nephritis (Fig. 1c).
Then, to study the formation and repair of DNA
double-strand breaks, γH2AX foci as a marker of DNA
damage and the formation of Rad51 foci as a marker of
homologous recombination were determined. In all sub-
jects analyzed, γH2AX foci reached maximal levels
within 8 h; thereafter, their levels were decreased, with
the removal capacity being higher in healthy controls
than in SLE patients (Fig. 2a, b). Increased γH2AX levels
were found in lupus nephritis compared to quiescent
SLE patients; statistical significance was observed at 2 h
and 48 h following melphalan treatment (Fig. 2b). In ac-
cordance to these results, higher γH2AX foci burden,
expressed as AUC, was observed in quiescent SLE
patients compared to healthy controls, whereas patients
with active proliferative nephritis showed higher γH2AX
burden than quiescent SLE patients (Fig. 2c). The Rad51
response followed the same time course as the γH2Ax
response, peaking at 8 h and declining thereafter, with
healthy controls showing lower Rad51 foci levels com-
pared to quiescent SLE patients (Fig. 2d-f ).
Apoptosis rates of quiescent SLE-derived mononuclear
cells correlate inversely with DNA repair efficiencies
The melphalan-induced apoptosis rates in PBMCs from
quiescent SLE patients and their matched healthy
Fig. 1 Impaired nucleotide excision repair in SLE patients.
a Representative autoradiograms for the Southern blot analysis
of melphalan-induced N-ras-specific DNA adducts. 0/0, no treatment.
The kinetics of monoadducts (b) and total amounts of monoadducts
expressed as AUC (c) in quiescent systemic lupus erythematosus (QSLE)
and lupus nephritis (LN) patients as well as in 12 healthy controls
(HC) are shown. The asterisks indicate significant differences (p < 0.05)
between QSLE and LN patients. The experiments shown were based
on a minimum of three independent repeats and the data reported
are the mean ± SD of all subjects analyzed
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controls were also measured. We found that the lowest
concentrations of melphalan required for the induction
of apoptosis were significantly higher in healthy controls
than in quiescent SLE patients (Fig. 3a), indicating that
PBMCs from quiescent SLE patients are characterized
by increased apoptotic rates. Interestingly, an inverse
correlation was observed between the melphalan con-
centration required for the induction of apoptosis and
the levels of both types of DNA damage examined in the
same quiescent SLE patients (linear regression analysis;
Fig. 2 Impaired double-strand breaks repair in quiescent SLE patients. a Typical images showing the γH2AX staining at different time points after
treatment of PBMCs from one representative healthy control (HC) and one quiescent systemic lupus erythematosus (QSLE) patient after treatment
with melphalan. Cell nuclei labeled with DAPI, γH2AX staining, as well as merged DAPI and γH2AX staining are shown. 0/0 no treatment. Formation
of γH2AX foci (b) and total amounts of γH2AX foci expressed as AUC (c) after treatment of PBMCs from QSLE and lupus nephritis (LN) patients as well
as from 12 HC with melphalan. The asterisks indicate significant differences (p < 0.05) between QSLE and LN patients. NSD no significant
difference. d Typical images showing the Rad51 staining at different time points after treatment of PBMCs from one representative HC
and one QSLE patient with melphalan. Cell nuclei labeled with DAPI, Rad51 staining, as well as merged DAPI and Rad51 staining are
shown. 0/0 no treatment. Formation of Rad51 foci (e) and total amounts of Rad51 foci expressed as AUC (f) after treatment of PBMCs
from QSLE patients and their matched HC with melphalan. The experiments shown were based on a minimum of three independent
repeats and the data reported are the mean ± SD of all subjects analyzed
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monoadducts: r2 = 0.831 for quiescent SLE patients and
0.920 for their matched controls, Fig. 3b; double-strand
breaks: r2 = 0.878 for quiescent SLE patients and 0.907
for healthy controls, Fig. 3c). Notably, a strong correl-
ation was found between the individual efficiencies of
the two DNA repair mechanisms under study in all sub-
jects analyzed (linear regression analysis: r2 = 0.767 for
SLE patients and 0.567 for healthy controls, Fig. 3d).
Defective chromatin organization and nucleotide excision
repair in quiescent SLE are partially corrected by
vorinostat
We next analyzed chromatin condensation in the N-ras
gene locus, using micrococcal nuclease digestion of un-
treated PBMCs from quiescent SLE patients and their
matched controls. As shown in Fig. 4a and b, patients
are characterized by more condensed chromatin at the
N-ras locus than their matched controls. That is, in
healthy controls the N-ras gene locus gave rise mostly to
mono- and di-nucleosome structures, with a significant
portion in mono-nucleosomes, while the same locus in
quiescent SLE patients gave rise to di-, tri-nucleosomes
and higher structures.
Chromatin organization and the efficiency of nucleo-
tide excision repair were also evaluated in the N-ras
gene locus following treatment of PBMCs from quies-
cent SLE with vorinostat, a histone deacetylase inhibitor
which has been approved by the US Food and Drug
Administration for the treatment of refractory cutaneous
T-cell lymphoma [24]. First, we determined the degree
of H4 histone acetylation in PBMCs from quiescent SLE
patients after treatment with vorinostat using Western
blot analysis; nonacetylated histone H4 was included as
a control for acetylated histone H4. We found that be-
fore incubation with vorinostat, the levels of acetylated
histone H4 were low and did not increase remarkably
with up to 1 μM vorinostat for 24 hours. However, incu-
bation with 2.5 μM vorinostat for 24 h resulted in the
maximal accumulation of acetylated histone H4 (Fig. 4d)
associated with chromatin decondensation (Fig. 4c). In
line with previous data showing that the rate of repair of
UV-induced DNA damage increased following histone
hyperacetylation by sodium butyrate [25], we found that
vorinostat treatment of PBMCs from quiescent SLE
patients resulted in increased efficiency of nucleotide
excision repair (Fig. 4e) and decreased DNA damage
burden of these cells (Fig. 4f ). Conversely, following
treatment of PBMCs from quiescent SLE patients
with a-amanitin, an inhibitor of RNA polymerase II,
which causes conversion of chromatin into a more
Fig. 3 Increased apoptosis rates of quiescent SLE-derived mononuclear cells correlate with defective DNA repair efficiencies. a The induction of
apoptosis after treatment of PBMCs from quiescent systemic lupus erythematosus (SLE) patients and their matched healthy controls (HC) with
melphalan. Correlation between the melphalan doses required for the induction of apoptosis and the drug-induced monoadducts (b) or double-
strand breaks levels (c) in the same QSLE patients or healthy controls. d Correlation between individual efficiencies of nucleotide excision repair
versus double-strand breaks repair (expressed as AUC) in all SLE patients (six with quiescent disease and six with proliferative nephritis) and 12
healthy controls. The experiments shown were based on a minimum of three independent repeats and the data reported are the mean ± SD of
all the subjects analyzed
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condensed form [16], chromatin compaction of the
N-ras gene locus (Additional file 1: Figure S1a, b)
was accompanied by reduction of the efficiency of
nucleotide excision repair and increased DNA damage
burden (Additional file 1: Figure S1c, d).
Vorinostat ameliorates DNA double-strand breaks repair
efficiency and decreases apoptosis rates in quiescent SLE
The effects of the chromatin organization modifiers on
the efficiency of double-strand breaks repair and the
apoptosis rates were also evaluated. In line with previous
data showing that the compaction of chromatin influ-
ences the efficiency of the DNA damage response and
the sensitivity of cells to DNA double-strand breaks
[26], we found that vorinostat treatment of PBMCs
from quiescent SLE patients increased the repair effi-
ciency of double-strand breaks (Fig. 4g), reduced
double-strand breaks burden (Fig. 4h), and suppressed
apoptosis rates of these cells (Fig. 4i). Conversely, in
all subjects, treatment of PBMCs with a-amanitin
resulted in higher double-strand breaks levels and
increased apoptosis rates (Additional file 1: Figure
S1e-g). Under the conditions used in this study, vori-
nostat or a-amanitin alone did not induce apoptosis
in PBMCs from all subjects examined (data not
shown).
Altered expression of DNA repair- and apoptosis-related
genes in quiescent SLE
The expression of genes involved in DNA damage repair
and apoptosis pathways was analyzed in untreated
PBMCs by RT2 Profiler™ PCR Array (Fig. 5a). Of 84
genes examined, a total of 37 genes representing several
non-mutually exclusive categories demonstrated at least
twofold difference in gene expression between healthy
controls and quiescent SLE patients (Additional file 1:
Tables S2 and S3). Particularly, the downregulated genes
were categorized into nucleotide excision repair (DDB1,
ERCC2, XPA, XPC), double-strand breaks repair (BLM,
CHEK1, HUS1, MRE11A, NBN, RAD50, RAD51, RPA1,
TP53BP1, XRCC2, XRCC6), base excision repair (LIG1,
PARP1, XRCC1), mismatch repair (MLH1, MLH3) and
signaling pathways (ATM, RAD1) (Fig. 5b). The expres-
sion of the DNA repair XRCC3 gene was also found
decreased in SLE patients. On the other hand, several
overexpressed genes are implicated in the apoptosis
pathway, including PPP1R15A, CDKN1A, BARD1,
RAD21, RAD9A, PRKDC, CIB1, BRCA1, ABL1, CHEK2
and BBC3 (Fig. 5c). Also, GADD45A, involved in DNA
repair, and H2AFX, a DNA damage response gene, were
overexpressed in lupus PBMCs.
Finally, we performed a systems biology analysis of the
significantly differentially expressed transcripts on
canonical pathways through IPA®, which revealed
significant involvement (enrichment p value < 0.05) of
several DNA damage response and repair pathways,
including nucleotide excision repair (p = 1.00E-007;
Additional file 1: Figure S2), homologous recombin-
ation (p = 5.01E-020; Additional file 1: Figure S3),
nonhomologous end joining (p = 2.51E-017; Additional
file 1: Figure S4), base excision repair (p = 2.63E-010;
Additional file 1: Figure S5), ATM signaling (p =
1.58E-043; Additional file 1: Figure S6), mismatch
repair (p = 3.16E-014; Additional file 1: Figure S7), as
well as apoptosis pathway signaling (p = 3.16E-003).
Given that the enrichment analysis was performed on
the differentially expressed genes only, the fact that
most of the preselected genes were differentially
expressed enhances the initial working hypothesis.
Discussion
Herein, two major DNA repair mechanisms were evalu-
ated ex vivo in patients with quiescent SLE and active
lupus nephritis. The first mechanism, namely nucleotide
excision repair was found to be less efficient in SLE pa-
tients compared to healthy controls, whereas patients
with quiescent disease showed higher repair efficiency
than those with active nephritis. Since the specific chro-
matin environment of a DNA lesion is considered an
important factor that may affect recognition of lesions
and repair rates [16, 27], a possible explanation for the
lower efficiency of nucleotide excision repair could be
related to a defective chromatin organization in our pa-
tients. Indeed, we found that quiescent SLE patients are
characterized by more condensed local chromatin than
healthy controls, which possibly impedes the access of
DNA repair proteins to sites of DNA damage, thus redu-
cing DNA repair capacity [28].
Whether a defective chromatin organization in SLE is as-
sociated with aberrations in histone acetylation processes
remains unclear. In general, histone acetyltransferases and
deacetylases regulate chromatin accessibility by adding or
removing, respectively, acetyl groups to lysine residues in
the N-terminal histone domains [29]. Acetylation neutral-
izes the positive charge of histone lysines, weakening elec-
trostatic DNA-histone interactions and increasing DNA
accessibility, while deacetylation strengthens DNA-histone
interactions, thus decreasing DNA accessibility. Regarding
the patterns of histone modifications in SLE patients, con-
troversial results have been reported. For example, Zhou et
al. [30] reported that histone H3 acetylation of the TNFSF7
(CD70) promoter in SLE CD4 +T cells is significantly in-
creased, and may contribute to the development of lupus
by increasing the expression of the CD70 gene. In addition,
in monocytes isolated from SLE patients, Zhang et al. [31]
identified a group of 179 genes with significantly enriched
acetylation of H4 promoter compared to controls. Other
data showed significantly increased total histone H4
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acetylation in SLE monocytes [32]. In contrast to the
above, and in line with our findings, global hypoacetylation
of histone H3 and H4 was observed in active lupus CD4+
T cells compared with controls [33]. Notably, the degree of
histone H3 acetylation correlated inversely with SLE dis-
ease activity [33].
The second major mechanism studied herein, namely
DNA double-strand breaks repair, was also found less
efficient in SLE patients compared to healthy controls,
with the DNA double-strand breaks burden being higher
in patients with active nephritis compared to those with
quiescent SLE. These results are in line with recent data
showing that both T cells and monocytes in SLE patients
have increased sensitivity to acquire double-strand
breaks following oxidative stress, which associates with
disease activity [34]. Although we did not address the
mechanistic basis for the decreased double-strand breaks
repair efficiency of our patients, previous studies have
Fig. 4 Effects of vorinostat treatment of quiescent SLE-derived cells. Autoradiograms showing micrococcal nuclease sensitivity of the N-ras locus
in untreated PBMCs from six healthy controls (HC) (a) and six quiescent systemic lupus erythematosus (QSLE) patients (b), as well as in PBMCs
from the same QSLE patients after treatment with 2.5 μM vorinostat for 24 h (c). Symbols M, D and T represent the positions of nucleosome
monomer, dimer and trimer respectively. d Western blot analysis of PBMCs from a representative quiescent SLE patient treated with various doses
of vorinostat for 24 h. Nonacetylated histone H4 was used as a control for acetylated histone H4, and beta actin as a loading control. The kinetics
of monoadducts (e) and γH2AX foci (g) as well as total amounts of monoadducts (f) and γH2AX foci expressed as AUC (h) after treatment of
PBMCs from QSLE patients and their matched healthy controls with melphalan in the presence or not of vorinostat. The asterisks indicate significant
differences (p < 0.05) between QSLE and LN patients. i The induction of apoptosis after treatment of PBMCs from the same QSLE patients and their
matched HC with melphalan in the presence or not of vorinostat. The experiments shown were based on a minimum of three independent repeats
and the data reported are the mean ± SD of all the subjects analyzed.
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shown that many repair proteins implicated in this
repair mechanism are targets for autoantibodies. For
example, autoantibodies against DNA repair proteins in-
volved in nonhomologous end joining, including the two
subunits of Ku protein, the poly(ADP-ribose) polymerase
1 (PARP-1) protein, the catalytic subunit of the DNA-
dependent protein kinase (DNA-PK) and the DNA ligase
IV were all identified in patients with systemic auto-
immune diseases [35–38]. Moreover, a cell-penetrating
lupus autoantibody, 3E10, was found to preferentially bind
DNA single-strand tails and inhibit key steps in DNA
single- and double-strand breaks repair process [39].
Interestingly, we found that the individual capacities of
both nucleotide excision repair and double-strand breaks
repair mechanisms strongly correlated with the corre-
sponding PBMCs apoptosis rates, in either SLE patients or
healthy controls, supporting our hypothesis that accumu-
lation of DNA damage contributes to increased apoptosis.
Following our assumption that the more condensed
chromatin in our quiescent lupus patients is linked to
deficient DNA repair, we considered that chemical mod-
ifiers of chromatin organization would affect repair effi-
ciency. Indeed, we found that treatment of PBMCs from
quiescent SLE patients with the histone deacetylase
inhibitor vorinostat resulted in hyperacetylation of his-
tone H4, chromatin decondensation, amelioration of
both nucleotide excision repair and DNA double-strand
breaks repair efficiencies, and decreased apoptosis. Pre-
vious studies have shown that the in vivo administration
of several histone deacetylase inhibitors including vori-
nostat, corrected the site-specific hypoacetylation states
on H3 and H4 lupus mouse models with marked
improvement of disease phenotype [40–42].
In line with the data presented above, gene expression
results showed that many genes involved in DNA dam-
age repair and signaling pathways were downregulated
in quiescent SLE patients, whereas, several genes
Fig. 5 Expression of 84 genes involved in DNA damage response pathways. a Hierarchical clustergram of the 84 genes under study in untreated
PBMCs from six quiescent systemic lupus erythematosus (QSLE) patients versus their matched healthy controls (HC). b, c Genes demonstrating
at least twofold difference in the transcription activity between QSLE patients and their matched HC. Gene acronyms are explained in
Additional file 1: Tables S2 and S3
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implicated in the apoptosis pathway were upregulated.
To the best of our knowledge, this is the first study in
SLE patients showing underexpression of the XPA, XPC,
HUS1, MRE11A, NBN, RAD50, RAD51, RPA1, TP53BP1
and ATM genes involved in DNA damage repair and
signaling pathways, as well as overexpression of
PPP1R15A, BARD1, BBC3, BRCA1 genes involved in
the apoptosis pathway. Moreover, in accordance to
previous studies, we found downregulation of the ex-
cision repair cross-complementing ERCC2 and ERCC5
genes [43, 44], the X-ray repair cross-complementing
XRCC6 gene [44], the DDB1 gene coding for the
damage-specific DNA binding protein 1 [45], the
Bloom syndrome RecQ helicase-like gene (BLM) [46],
the XRCC1 gene [11] and the poly (ADP-ribose) poly-
merase 1 gene (PARP-1) [47]. Also, we found that
SLE cells showed higher GADD45A mRNA levels as
compared with healthy controls [48]. Overexpression
of several other apoptosis-related genes has also been
reported in PBMCs from SLE patients [49].
Regarding the pathogenetic mechanisms of auto-
immunity, an important link between DNA damage
repair and the activation of the type I interferon
(IFN) characterizing SLE emerges [50, 51]. Indeed,
Gunther et al. [52] reported recently that rare vari-
ants of the genome surveillance enzyme ribonuclease
H2 gene are associated with systemic autoimmunity
and that these variants resulted in impaired ribonu-
cleotide removal. They also showed that such embed-
ded ribonucleotides caused increased UV-induced
cyclobutane pyrimidine dimer formation and en-
hanced type I IFN signaling, thus linking mutations
in a DNA repair enzyme with systemic autoimmunity.
Furthermore, Härtlova et al. [53] showed that accu-
mulation of spontaneous DNA lesions stimulates type
I IFN system via the activation of the STING pathway
by self-DNA released into the cytoplasm, implying
that the DNA repair network emerges as an import-
ant new player in the pathogenesis of autoimmunity.
Moreover, a polymorphism in the DNA repair gene
RAD51B has been associated with increased risk of
SLE [54].
A limitation of the present work is the small sample
size of patients with quiescent SLE; increasing the num-
ber of patients would increase confidence in the data
generated. However, the main conclusion of this study,
i.e., that both nucleotide excision repair and DNA
double-strand breaks repair were defective in SLE pa-
tients (a) was confirmed in both quiescent SLE and
in lupus nephritis patients (12 SLE patients versus 12
healthy controls) and (b) is in line with previous data
showing that SLE T cells and monocytes have in-
creased sensitivity to acquiring DNA double-strand
breaks in response to oxidative stress [34]. Moreover,
since total PBMCs were used in the present study, we
cannot exclude the possibility that differences in cell
subsets constituents between patients and controls
contribute to some of the differences observed.
Notably, a recent report provides evidence for defect-
ive repair of oxidative stress-induced double-strand
breaks in all peripheral blood mononuclear cell sub-
sets (CD4+ T cells, CD8+ T cells and monocytes) de-
rived from SLE patients compared with those from
healthy controls [34]. Also, previous studies have also
shown that both lymphocytes and neutrophils from
SLE patients display increased DNA damage and,
additionally, may demonstrate defective repair of oxi-
dative DNA damage [9, 10].
Conclusions
Our findings support the hypothesis that increased
apoptosis in SLE could be due, at least in part, to defect-
ive DNA repair and chromatin organization (Fig. 6).
Based on our findings we propose that SLE patients, for
reasons currently unknown, are characterized by con-
densed chromatin in certain loci, resulting in lower
repair efficiency of important DNA repair pathways
(nucleotide excision repair and DNA double-strand
breaks repair) and, thus, increased DNA damage bur-
den, which in turn triggers the induction of the apop-
totic pathway. Although not tested in vivo, i.e., in
lupus mouse models, treatment of human SLE-
Fig. 6 Epigenetically regulated functional abnormalities of DNA
repair machinery may promote lymphocyte apoptosis in SLE: a
proposed model (for details see “Conclusions”)
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derived cells with the histone deacetylase inhibitor
vorinostat results in chromatin decondensation, ameli-
oration of DNA repair efficiency, and decreased apop-
tosis. Therefore, further work on the mechanisms of
the epigenetic imbalance in DNA damage repair may
reveal potential therapeutic targets in SLE.
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